CBE04BB7-A357-484D-BFDB-2CAEEC629123
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 23.19316688567674
- age_years
- 35
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.615
- MYC_TARGETS_V1+0.518
- OXIDATIVE_PHOSPHORYLATION+0.511
- UNFOLDED_PROTEIN_RESPONSE+0.499
- MTORC1_SIGNALING+0.427
- DNA_REPAIR+0.415
- HEDGEHOG_SIGNALING+0.356
- P53_PATHWAY+0.335
- E2F_TARGETS+0.332
- GLYCOLYSIS+0.314
Top 10 suppressed
- KRAS_SIGNALING_DN-0.288
- SPERMATOGENESIS-0.288
- ALLOGRAFT_REJECTION-0.238
- INFLAMMATORY_RESPONSE-0.227
- BILE_ACID_METABOLISM-0.225
- INTERFERON_ALPHA_RESPONSE-0.207
- COMPLEMENT-0.206
- APICAL_SURFACE-0.197
- MYOGENESIS-0.197
- INTERFERON_GAMMA_RESPONSE-0.185
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12696801 | — | — | 0.848 |
| 2 | A21DDF04-BECE-498B-81EA-F6953CD30D82 | — | — | 0.839 |
| 3 | 1F4CD8D0-E2FD-45AA-8CE2-8C0488916778 | — | — | 0.829 |
| 4 | 6F0A1EAE-1DBE-4C19-BC3A-DB41CE9C56DA | — | — | 0.818 |
| 5 | 58A2E073-D3DE-44B2-9065-3DE14B53B3A2 | — | — | 0.814 |
| 6 | FB7673F7-FF7F-4C3C-A8C6-9C11C6BB71D5 | — | — | 0.804 |
| 7 | R205 | — | — | 0.803 |
| 8 | DAE9D154-5E0C-4961-9110-9E5653AAA787 | — | — | 0.801 |
| 9 | SAMN03290906 | — | — | 0.793 |
| 10 | SRR934967 | — | — | 0.792 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.615 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.518 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.511 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.499 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.427 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.415 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.356 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.335 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.332 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.314 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.280 | Remibrutinib | — uncovered |
| HYPOXIA | 0.273 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.227 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.224 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.215 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.202 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.178 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.170 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.167 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.151 | Inavolisib | — uncovered |